RCT Glargine vs NPH for Treatment of DM in Pregnancy

Last updated: September 26, 2024
Sponsor: Loyola University
Overall Status: Active - Recruiting

Phase

3

Condition

Diabetes Prevention

Diabetes And Hypertension

Diabetes Mellitus, Type 2

Treatment

insulin NPH

Insulin glargine

Clinical Study ID

NCT06619301
217918
  • Ages > 18
  • Female

Study Summary

We are asking you to take part in this research study because you are diagnosed with pregestational Type 2 Diabetes Mellitus or Gestational Diabetes Mellitus requiring insulin therapy in pregnancy. Currently, many hospitals differ among use of insulin for management of DM in pregnancy, with NPH, glargine and detemir being the most commonly used forms of basal insulin. Outside of pregnancy, NPH is rarely used with glargine and determir being the more common forms of insulin used due to their fewer episodes of hypoglycemia in these patients. Detemir has been well studied in pregnancy and found to be noninferior to NPH. Unfortunately, glargine has not been as well studied in pregnancy. Thus, with this study we want to compare glargine and NPH.

The purpose of this study is to compare two different forms of insulin (Glargine and NPH) that we regularly use to manage diabetes mellitus in pregnancy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient requiring initiation of insulin therapy for Gestational Diabetes Mellitus orType 2 Diabetes Mellitus in pregnancy

  • At least 18 years old

  • Insulin started prior to 34 weeks gestation

  • Established prenatal care by 14 weeks gestation

Exclusion

Exclusion Criteria:

  • Those under the age of 18 years old

  • Those unable to consent in english

  • Allergy to insulin

  • Controlled with only diet modification or the use of oral antihyperglycemics

  • Has diagnosis of Type 1 Diabetes Mellitus

  • Receiving insulin through an insulin pump

Study Design

Total Participants: 160
Treatment Group(s): 2
Primary Treatment: insulin NPH
Phase: 3
Study Start date:
April 01, 2024
Estimated Completion Date:
January 01, 2027

Study Description

This is an open-label, noninferiority, prospective randomized study. Patients will be randomized to either be treated with NPH insulin for management of diabetes mellitus in pregnancy, or with Glargine insulin. We will include all pregnant patients managed by the Maternal Fetal Medicine team at Loyola University of Medical Center that have pregestational Type 2 Diabetes Mellitus or Gestational Diabetes Mellitus requiring insulin. Our primary outcome is hypoglycemia.

We provide patients with insulin teaching, a referral to diabetic nutrition education, and instructions for hypoglycemic events. Patients are instructed to continue monitoring blood glucose 4 times a day (fasting and 2 hours after each meal), log their blood glucose values in MyLoyola chart, continue routine prenatal care with maternal fetal medicine/high risk obstetric clinic, and continue routine ultrasound with serial growth ultrasounds and antenatal fetal surveillance. The study is voluntary, and the patients will receive the same care and number of visits regardless of whether they choose to participate in the study or not, regardless of which arm they are in within the RCT.

Connect with a study center

  • Loyola University Medical Center

    Maywood, Illinois 60153
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.